Tuberculosis

PubMed Free Full Text

Tuberculosis: treatment

Africa

• Clinical and Translational Science
  • Pharmacogenetics as part of recommended precision medicine for tuberculosis treatment in African populations: Could it be a reality? [2023]

• PLoS ONE
  • Tuberculosis treatment intervention trials in Africa: A cross-sectional bibliographic study and spatial analysis [2021]

Asia

• BMJ Global Health
  • Prevalence and predictive factors of tuberculosis treatment interruption in the Asia region: a systematic review and meta-analysis [2023]

Australia

• Queensland Health
  • Treatment of Tuberculosis in Adults and Children

Brazil

• BMC Health Services Research
  • Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services [2016]

• BMC Public Health
  • Machine learning algorithms using national registry data to predict loss to follow-up during tuberculosis treatment [2024]
  • Factors associated with the rapid implementation process of the fixed-dose combination RHZE tuberculosis regimen in Brazil: an ecological study [2013]

• Ciência & Saúde Coletiva
  • Vulnerable populations and tuberculosis treatment outcomes in Brazil [2021]

• Epidemiologia e Serviços de Saúde
  • Trend of epidemiological indicators and factors associated with tuberculosis treatment dropout and death among street people in Brazil: an ecological and cross-sectional study, 2014-2022 [2025]

• Jornal Brasileiro de Pneumologia
  • A critical analysis of the decreasing trends in tuberculosis cure indicators in Brazil, 2001-2022 [2024]
  • Analysis and comparison of tuberculosis treatment outcomes in the homeless population and in the general population of Brazil [2021]
  • Evaluation of the impact that the changes in tuberculosis treatment implemented in Brazil in 2009 have had on disease control in the country [2017]

• Lancet Global Health
  • Social and health factors associated with unfavourable treatment outcome in adolescents and young adults with tuberculosis in Brazil: a national retrospective cohort study [2021]

• Revista da Sociedade Brasileira de Medicina Tropical
  • Factors Associated with the Abandonment of Tuberculosis Treatment in Brazil: A Systematic Review [2023]

Canada

• Canadian Agency for Drugs and Technologies in Health
  • Shortened Drug Regimens for the Treatment of Active Tuberculosis [2021]
  • Incentives and Support Programs to Improve Adherence to Tuberculosis Treatment [2021]
  • Treatment of Tuberculosis: A Review of Guidelines [2020]
  • Direct Observational Therapy for the Treatment of Tuberculosis: A Review of Clinical Evidence and Guidelines [2020]

• Canadian Thoracic Society
  • Treatment of tuberculosis disease [2022]

China

• BMC Public Health
  • Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review [2011]

• China CDC Weekly
  • Health Facilities and Treatment Service Models of the National Tuberculosis Program — China, 2010-2020 [2021]

• Infectious Diseases of Poverty
  • Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study [2016]
  • The production and sales of anti-tuberculosis drugs in China [2016]
  • Implementing a “free” tuberculosis (TB) care policy under the integrated model in Jiangsu, China: practices and costs in the real world [2016]

Colombia

• Revista Española de Quimioterapia
  • Antimycobacterial natural products--an opportunity for the Colombian biodiversity [2011]

Denmark

• BMC Health Services Research
  • Review of tuberculosis treatment outcome reporting system in Denmark, a retrospective study cohort study from 2009 through 2014 [2020]

• Scientific Reports
  • Predictors for Pulmonary Tuberculosis Treatment Outcome in Denmark 2009–2014 [2019]

Ethiopia

• BMJ Global Health
  • Modelling the epidemiological and economic impact of digital adherence technologies with differentiated care for tuberculosis treatment in Ethiopia [2024]

• PLoS ONE
  • Treatment seeking delay and associated factors among tuberculosis patients attending health facility in Ethiopia from 2000 to 2020: A systematic review and meta analysis [2021]

Europe

• European Centre for Disease Prevention and Control
  • Expert Opinion on the introduction of new drugs for tuberculosis control in the EU/EEA [2015]

• European Respiratory Journal
  • Rifapentine access in Europe: growing concerns over key tuberculosis treatment component [2022]
  • Tuberculosis treatment outcome monitoring in European Union countries: systematic review [2013]

• EuroSurveillance
  • Tuberculosis treatment outcome in the European Union and European Economic Area: an analysis of surveillance data from 2002-2011 [2015]

Europe, United States

• American Thoracic Society
  • Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline [2025]

Finland

• BMC Public Health
  • Risk factors affecting treatment outcomes for pulmonary tuberculosis in Finland 2007–2014: a national cohort study [2020]

France

• EuroSurveillance
  • Tuberculosis treatment outcomes of notified cases: trends and determinants of potential unfavourable outcome, France, 2008 to 2014 [2020]

Gambia

• International Journal of Tuberculosis and Lung Disease
  • The household economic burden of drug-susceptible TB diagnosis and treatment in The Gambia [2022]

Germany

• ERJ Open Research
  • Cost of illness of non-multidrug-resistant tuberculosis in Germany: an update [2020]

• EuroSurveillance
  • Find and treat or find and lose? Tuberculosis treatment outcomes among screened newly arrived asylum seekers in Germany 2002 to 2014 [2018]

Ghana

• International Journal of Mycobacteriology
  • Medicinal plants used to treat TB in Ghana [2015]

High-income countries

• Patient preference and adherence
  • Relational Dynamics of Treatment Behavior Among Individuals with Tuberculosis in High-Income Countries: A Scoping Review [2021]

India

• Lancet Infectious Diseases
  • The number of privately treated tuberculosis cases in India: an estimation from drug sales data [2016]

• Lung India
  • DOTS for TB relapse in India: A systematic review [2012]

• PLoS ONE
  • A model-based investigation into urban-rural disparities in tuberculosis treatment outcomes under the Revised National Tuberculosis Control Programme in India [2020]
  • Are Tuberculosis Patients in a Tertiary Care Hospital in Hyderabad, India Being Managed According to National Guidelines? [2012]

• Public Health Action
  • How much do Indians pay for tuberculosis treatment? A cost analysis [2020]

India, Philippines, South Africa

• Lancet Global Health
  • Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis [2024]

Indian subcontinent

• BMJ Open
  • Patient adherence to tuberculosis treatment in the Indian subcontinent: systematic review and meta-synthesis of qualitative research [2023]

Indonesia

• Journal of Multidisciplinary Healthcare
  • COVID-19 Pandemic Disruption on the Management of Tuberculosis Treatment in Indonesia [2022]

• PLoS ONE
  • Nonadherence to anti-tuberculosis treatment, reasons and associated factors among pulmonary tuberculosis patients in the communities in Indonesia [2023]

International

• BMC Health Services Research
  • Evidence of tuberculosis treatment outcomes among people experiencing homelessness: a scoping review [2025]

• BMJ Global Health
  • Cost and cost-effectiveness of digital technologies for support of tuberculosis treatment adherence: a systematic review [2024]
  • Estimating the prevalence of poor-quality anti-TB medicines: a neglected risk for global TB control and resistance [2023]

• Bulletin of the World Health Organization
  • Target regimen profiles for tuberculosis treatment [2024]
  • Health literacy and tuberculosis control: systematic review and meta-analysis [2024]
  • Target product profiles: tests for tuberculosis treatment monitoring and optimization [2023]

• Clinical Microbiology and Infection
  • Tuberculosis treatment monitoring tests during routine practice: study design guidance [2024]

• Frontiers in Pharmacology
  • A Systematic Review of Economic Evaluations of Active Tuberculosis Treatments [2021]

• Frontiers in Public Health
  • A systematic review of economic evaluations of pharmacological treatments for active tuberculosis [2024]

• Globalization and Health
  • Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024 [2024]

• International Journal of Tuberculosis and Lung Disease
  • Clinical standards for the management of adverse effects during treatment for TB [2023]

• JMIR mHealth and uHealth
  • Digital Health Interventions to Enhance Tuberculosis Treatment Adherence: Scoping Review [2023]

• PLoS Medicine
  • Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons [2019]
  • Advances in clinical trial design for development of new TB treatments—Translating international tuberculosis treatment guidelines into national strategic plans: Experiences from Belarus, South Africa, and Vietnam [2019]

• PLoS ONE
  • Treatment for radiographically active, sputum culture-negative pulmonary tuberculosis: A systematic review and meta-analysis [2023]

• Systematic Reviews
  • Mapping the effectiveness of the community tuberculosis care programs: a systematic review [2023]

Japan

• Respirology
  • Safety of pyrazinamide in elderly patients with tuberculosis in Japan: A nationwide cohort study [2024]

• Western Pacific Surveillance and Response Journal
  • Delay in health-care-seeking treatment among tuberculosis patients in Japan: what are the implications for control in the era of universal health coverage? [2020]

Kenya

• Health and Human Rights Journal
  • Detention of People Lost to Follow-Up on TB Treatment in Kenya [2016]

• PLoS ONE
  • Using Survival Analysis to Identify Risk Factors for Treatment Interruption among New and Retreatment Tuberculosis Patients in Kenya [2016]

Latvia

• Public Health Action
  • Treatment outcomes among drug-susceptible tuberculosis patients in Latvia, 2006–2010 [2014]

Lebanon

• Ministry of Public Health
  • Updated National Guidelines for Drug Susceptible Tuberculosis [2023]

Low and middle income countries

• BMC Medicine
  • The impact of the COVID-19 pandemic on tuberculosis treatment outcomes in 49 high burden countries [2024]

• Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
  • Quality of tuberculosis care by pharmacies in low- and middle-income countries: Gaps and opportunities [2019]

Malaysia

• PLoS ONE
  • Determinants of unsuccessful treatment outcomes and mortality among tuberculosis patients in Malaysia: A registry-based cohort study [2020]

Mauritania

• PLoS ONE
  • A pharmaceutical monitoring system to assess the quality of antituberculosis drug products used in Mauritania [2023]

Moldova

• Public Health Action
  • Do incentives improve tuberculosis treatment outcomes in the Republic of Moldova? [2014]

Morocco

• PLoS ONE
  • Cost-effectiveness of a medication event monitoring system for tuberculosis management in Morocco [2022]

Nigeria

• World Journal of Methodology
  • Profile and determinants of unsuccessful tuberculosis outcome in rural Nigeria: Implications for tuberculosis control [2016]

Pakistan

• International Journal of Infectious Diseases
  • Detection of active mycobacterium tuberculosis at 6th month exit among declared successfully treated cases in Pakistan [2021]

Poland

• Frontiers in Public Health
  • The impact of comorbidities on tuberculosis treatment outcomes in Poland: a national cohort study [2023]

Republic of Korea

• Annals of Laboratory Medicine
  • Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations [2017]

• BMJ Open Respiratory Research
  • Real-world impact of the fixed-dose combination on improving treatment outcomes of drug-susceptible tuberculosis: a comparative study using multiyear national tuberculosis patient data [2023]

• Frontiers in Public Health
  • Beyond reducing direct medical cost: examining health outcomes in tuberculosis through a difference-in-differences analysis of South Korea's out-of-pocket payment exception policy [2024]

• International Journal of Health Policy and Management
  • Effect of Cost-Exemption Policy on Treatment Interruption in Patients With Newly Diagnosed Pulmonary Tuberculosis in South Korea [2024]

• Journal of Infection and Public Health
  • Cost-effectiveness of improving patients' adherence to tuberculosis treatment in South Korea using discrete event simulation [2024]

• Journal of Korean Medical Science
  • Increased Healthcare Delays in Tuberculosis Patients During the First Wave of COVID-19 Pandemic in Korea: A Nationwide Cross-Sectional Study [2022]

• Journal of Preventive Medicine and Public Health
  • Cohort Profile: Korean Tuberculosis and Post-Tuberculosis Cohort Constructed by Linking the Korean National Tuberculosis Surveillance System and National Health Information Database [2022]

• Medicine
  • Factors related to self-care in Korean patients with tuberculosis: A systematic review and meta-analysis [2024]

• Public Health
  • Low household income increases the risk of tuberculosis recurrence: a retrospective nationwide cohort study in South Korea [2024]

South Africa

• Health and Quality of Life Outcomes
  • Health-related quality of life and its association with medication adherence in active pulmonary tuberculosis– a systematic review of global literature with focus on South Africa [2016]

• National Department of Health South Africa
  • National Guidelines on the Treatment of Tuberculosis Infection [2023]

• PLoS ONE
  • The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa [2015]

• Scientific Reports
  • Mortality during tuberculosis treatment in South Africa using an 8-year analysis of the national tuberculosis treatment register [2021]

• South African Medical Journal
  • Evaluation of adherence to national treatment guidelines among tuberculosis patients in three provinces of South Africa [2014]

South-East Asia

• Medical Journal of Malaysia
  • A scoping review on socioeconomic factors affecting tuberculosis loss to follow-up in Southeast Asia [2024]

Spain

• Archivos de Bronconeumología
  • Spanish Compliance With Guidelines for Prescribing Four Drugs in the Intensive Phase of Standard Tuberculosis Treatment [2016]

Sub-Saharan Africa

• African Health Sciences
  • A review of compliance to anti tuberculosis treatment and risk factors for defaulting treatment in Sub Saharan Africa [2010]

• Global Health Action
  • Barriers to initiating tuberculosis treatment in sub-Saharan Africa: a systematic review focused on children and youth [2017]

• International Journal of Environmental Research and Public Health
  • Tuberculosis Treatment Outcome and Predictors in Africa: A Systematic Review and Meta-Analysis [2021]

• Patient preference and adherence
  • An ontology for factors affecting tuberculosis treatment adherence behavior in sub-Saharan Africa [2016]

• Pharmacogenomics
  • Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study [2015]

Taiwan

• PLoS ONE
  • Improved Consistency in Dosing Anti-Tuberculosis Drugs in Taipei, Taiwan [2012]

Thailand

• Scientific Reports
  • Catastrophic costs incurred by tuberculosis affected households from Thailand's first national tuberculosis patient cost survey [2024]

Uganda

• Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
  • Variation in tuberculosis treatment outcomes and treatment supervision practices in Uganda [2020]

• Value in Health
  • Cost and Cost-Effectiveness of a Digital Adherence Technology for Tuberculosis Treatment Support in Uganda [2022]

United Kingdom

• UK Health Security Agency
  • TB treatment in England, 2021

United States

• American Thoracic Society
  • Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis [2016]
  • An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy [2006]

• Centers for Disease Control and Prevention
  • Recommendations for Use of Video Directly Observed Therapy During Tuberculosis Treatment — United States, 2023 [2023]
  • Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022 [2022]
  • Treatment for Latent TB Infection and TB Disease

• Clinical Gastroenterology and Hepatology
  • Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity [2015]

Uzbekistan

• Health Economics Review
  • Health system support and health system strengthening: two key facilitators to the implementation of ambulatory tuberculosis treatment in Uzbekistan [2016]

• PLoS ONE
  • Factors Associated with Unfavorable Treatment Outcomes in New and Previously Treated TB Patients in Uzbekistan: A Five Year Countrywide Study [2015]

WHO

• World Health Organization
  • WHO consolidated operational handbook on tuberculosis: module 4: treatment and care [2025]
  • WHO consolidated guidelines on tuberculosis: module 4: treatment and care [2025]
  • Platform for efficient and practical tuberculosis treatment trials: meeting report, 30 September-1 October 2024, Geneva [2024]
  • Guidance on evidence generation on new regimens for tuberculosis treatment [2024]
  • Target regimen profiles for tuberculosis treatment, 2023 update [2023]
  • Target product profiles for tests for tuberculosis treatment monitoring and optimization [2023]
  • WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support [2022]
  • WHO consolidated guidelines on tuberculosis: module 4: treatment: tuberculosis care and support [2022]
  • WHO Operational Handbook on Tuberculosis, Module 4: Treatment - Drug-Susceptible Tuberculosis Treatment [2022]
  • WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Susceptible Tuberculosis Treatment [2022]
  • Treatment of drug-susceptible tuberculosis: rapid communication [2021]
  • Position statement on innovative clinical trial design for development of new TB treatments [2021]
  • Report of the technical consultation on advances in clinical trial design for development of new TB treatments: Glion-sur-Montreux, Switzerland, 14-16 March 2018 [2018]
  • Handbook for the use of digital technologies to support tuberculosis medication adherence [2017]
  • Guidelines for treatment of drug-susceptible tuberculosis and patient care [2017]
  • Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis [2017]
  • Active tuberculosis drug-safety monitoring and management (aDSM): Framework for implementation [2015]
  • Policy Implementation Package for new TB drug introduction [2014]
  • Green Light Committee application instructions [2010]
  • WHO policy on TB infection control in health-care facilities, congregate settings and households [2009]
  • Assessment of human resources and time needed to implement the DOTS strategy for TB control in health facilities : survey instrument and guide to implementation [2008]
  • Treatment of tuberculosis : guidelines for national programmes [2003]
  • Tuberculosis treatment success

{Related topics}

• Topic
  • Tuberculosis: drug resistance
  • Tuberculosis